EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study

Onyema Ogbuagu, Andrew Wiznia iD, Joseph P McGowan iD, Daniel S Berger, Catherine M Creticos, Debbie Hagins iD, Theo Hodge, Olayemi Osiyemi, James Sims, David A Wheeler, Hui Wang, Nicolas A Margot iD und 4 weitere

Open Forum Infectious Diseases · 26.12.2025 · 13 (1)

DOI: 10.1093/ofid/ofaf763 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 19.12.2025. Verfasst von Onyema Ogbuagu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lenacapavir is a twice-yearly HIV-1 capsid inhibitor approved, in combination with other antiretrovirals, for the treatment of heavily treatment-experienced people with multidrug-resistant HIV, based on the Phase 2/3 CAPELLA study. Here, we report week 156 efficacy and safety results.

Methods

In CAPELLA (NCT04150068), participants received 2-week oral lenacapavir lead-in doses, followed by subcutaneous lenacapavir every 6 months, combined with an investigator-selected optimized background regimen. Endpoints included virologic outcomes, CD4 cell count trends, adverse events, and treatment-emergent resistance.

Results

CAPELLA enrolled 72 participants: 25% female; 38% Black; median age, 52 years; CD4 cell count <200 cells/μL, 64% (<50 cells/μL, 22%). At week 156, 61% (43/70) had HIV RNA <50 copies/mL by FDA Snapshot Algorithm, 16% (11/70) had ≥50 copies/mL, and 23% (16/70) had missing data; by missing = excluded analysis, 85% (44/52) had HIV RNA <50 copies/mL. Mean CD4 cell count increase from baseline to week 156 was 164 cells/μL (95% CI: 116–211). Through week 156, 14/72 participants developed emergent LEN resistance. Injection site reactions were mostly Grade 1/2, and frequency declined over time. Through week 156, two participants discontinued lenacapavir due to Grade 1 injection site nodules.

Conclusions

Lenacapavir plus an optimized background antiretroviral regimen maintained a high rate of virologic suppression at week 156 with continued increases in CD4 counts. Lenacapavir was well tolerated with a favorable safety profile and very low rates of lenacapavir discontinuation. These data demonstrate longer-term efficacy and safety of lenacapavir for heavily treatment-experienced people with multidrug-resistant HIV.

Schlagwörter

Stichwörter der Autor:innen

HIV IHIV I - therapyHIV/AIDSHIV/AIDS - therapyinfectionsviruses

Autor:innen und Institutionen

  • Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Center for AIDS Research and Treatment, Northwell Health, Manhasset, New York, USA.
  • Northstar Healthcare, Chicago, Illinois, USA.
  • Howard Brown Health, Chicago, Illinois, USA.
  • Coastal District Care Clinic, Savannah, Georgia, USA.

ORCID-Profile: Andrew Wiznia, Joseph P McGowan, Debbie Hagins, Nicolas A Margot, Martin S Rhee, Sorana Segal-Maurer

Zitieren

APA

Ogbuagu, O., Wiznia, A., McGowan, J. P., Berger, D. S., Creticos, C. M., Hagins, D., Hodge, T., Osiyemi, O., Sims, J., Wheeler, D. A., Wang, H., Margot, N. A., Dvory-Sobol, H., Rhee, M. S., Segal-Maurer, S., & Molina, J. M. (2025). Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study. Open Forum Infectious Diseases, 13(1). https://doi.org/10.1093/ofid/ofaf763

Vancouver

Ogbuagu O, Wiznia A, McGowan JP, Berger DS, Creticos CM, Hagins D, et al. Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study. Open Forum Infectious Diseases. 2025;13(1). doi:10.1093/ofid/ofaf763

BibTeX
@article{Ogbuagu2025,
  author = {Ogbuagu, Onyema and Wiznia, Andrew and McGowan, Joseph P and Berger, Daniel S and Creticos, Catherine M and Hagins, Debbie and Hodge, Theo and Osiyemi, Olayemi and Sims, James and Wheeler, David A and Wang, Hui and Margot, Nicolas A and Dvory-Sobol, Hadas and Rhee, Martin S and Segal-Maurer, Sorana and Molina, Jean-Michel},
  title = {Subcutaneous Lenacapavir in People With Multidrug-Resistant HIV-1: 156 Week Results of the CAPELLA Study},
  journal = {Open Forum Infectious Diseases},
  year = {2025},
  volume = {13},
  number = {1},
  doi = {10.1093/ofid/ofaf763}
}
Kostenlos starten →